STAT

STAT+: Pharmalittle: Pharma prioritizes biologics over pills due to drug-pricing law; former Takeda employee accused of creating fake consulting firm

Drugmakers are prioritizing biologics over pills because under a new law, they have more time before becoming subject to Medicare price negotiations.
Source: Alex Hogan/STAT

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to and ). And what about you? This may be an opportunity to park yourself in front of the telly and catch up on your binge watching or, conversely, lively up yourself by venturing to a museum or danceteria. Or you could simply sit quietly and take stock of the rest of your life. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you on Tuesday due to a long holiday weekend on this side of the pond. …

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.

Related Books & Audiobooks